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Abstract
Background—In children with cystic fibrosis (CF), recovery from growth faltering within 2 
years of diagnosis (Responders) is associated with better growth and less lung disease at age 6 
years. This study examined whether these benefits are sustained through 12 years of age.
Methods—Longitudinal growth from 76 children with CF enrolled in the Wisconsin CF Neonatal 
Screening Project was examined and categorized into 5 groups: R12, R6, and R2, representing 
Responders who maintained growth improvement to age 12, 6, and 2 years, respectively, and I6 
and N6, representing Non-responders whose growth did and did not improve during ages 2–6 
years, respectively. Lung disease was evaluated by % predicted forced expiratory volume in one 
second (FEV1) and chest radiograph (CXR) scores.
Results—Sixty-two percent were Responders. Within this group, 47% were R12, 28% were R6, 
and 25% were R2. Among Non-responders, 76% were N6. CF children with meconium ileus (MI) 
had worse lung function and CXR scores compared to other CF children. Among 53 children with 
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pancreatic insufficiency without MI, R12 had significantly better FEV1 (97–99% predicted) and 
CXR scores during ages 6–12 years than N6 (89–93% predicted). Both R6 and R2 experienced a 
decline in FEV1 by ages 10–12 years.
Conclusions—Early growth recovery in CF is critical, as malnutrition during infancy tends to 
persist and catch-up growth after age 2 years is difficult. The longer adequate growth was 
maintained after early growth recovery, the better the pulmonary outcomes at age 12 years.
Keywords
growth; growth faltering; catch-up growth; pulmonary function; quantitative chest radiography; 
lung disease
INTRODUCTION
The associations between nutrition and pulmonary status in patients with cystic fibrosis (CF) 
have been reported.1–9 The positive association between better nutritional status in early life 
and better lung function in later years has led to the development of CF clinical practice 
guidelines for comprehensive nutrition management,10 in hopes of delaying progression of 
lung disease. The introduction of widespread newborn screening (NBS) for CF offers an 
opportunity to treat and prevent malnutrition.11–13 However, almost half of U.S. infants still 
demonstrate some degree of malnutrition in the first months of life.14
The present study represents the third of a series of Responder studies we conducted over 
the past decade. Responder I utilized an innovative concept of early weight recovery to 
define treatment responders within 2 years of diagnosis in infants with CF and identified 
factors associated with the likelihood of being Responders.15 Responder II examined 
whether Responders achieved better pulmonary status at 6 years of age when reliable 
pulmonary function data can be obtained in the majority of children with CF. We 
demonstrated that Responders had fewer cough symptoms, better lung function, and better 
chest radiograph scores at age 6 years compared to Non-responders.8
It is unknown if pulmonary benefits associated with early growth recovery experienced by 
the Responders are sustained beyond age 6 years. The present study, Responder III, was 
designed to fill in this gap of knowledge. Specifically, we examined: 1) whether Responders 
who maintained adequate growth during ages 2–6 years continued to do so through age 12 
years, 2) whether Non-responders continue to follow their respective growth trajectories 
during ages 6–12 years, and 3) the impact of growth during ages 6–12 years on pulmonary 
status at age 12 years in Responders and Non-responders.
MATERIALS AND METHODS
Study Population
The study population included 76 children with CF who were enrolled in the Wisconsin 
Randomized Clinical Trial of CF Neonatal Screening Project (WI-RCT) and had complete 
growth data and valid pulmonary function data through 12 years of age. The WI RCT is a 
prospective longitudinal investigation initiated in 1985 to assess the benefits and risks of 
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NBS for CF.13,16 Briefly, randomization of newborns occurred from 4/15/85 until 6/30/94; 
for half of the randomly assigned newborns, early diagnosis of CF was established through 
NBS, while the diagnosis of CF in newborns randomized to the control arm was generally 
established through signs and symptoms of CF. Longitudinal follow-up of the WI RCT 
cohort continued through 2011 until the youngest patient reached 17 years of age. The WI 
RCT was approved by the human subjects committee at the University of Wisconsin and the 
Research and Publications Committee/Human Rights Board at Children’s Hospital of 
Wisconsin.
A total of 138 children were enrolled in the WI RCT.12 The Responder I study included 100 
children who had complete data on growth, plasma fatty acid and dietary data in the first 2 
years of life with analyses focused on the subgroup of 80 subjects who had pancreatic 
insufficiency (PI) but no meconium ileus (MI).15 The Responder II study included 91 
children (9 children lost to follow up during 2–6 years of age)8 and the present study 
(Responder III) included 76 children (15 children lost to follow up during 6–12 years of 
age).
Growth assessment and definition of responders
Weight, recumbent length before age 2 years and standing height after age 2 years were 
measured every 3 months.11,12 Age- and sex-specific z-scores for weight (WTz), length/
height (HTz) and body mass index (BMIz) were computed by using the 2000 CDC growth 
charts,17 which were used in our Responder I and II studies and the recommended growth 
references for all ages before the CDC and the American Academy of Pediatrics 
recommended WHO growth charts for age 0–2 years in 2010 and 2012.18, 19 In addition, by 
using the CDC charts in the present Responder III study, we avoided the discrepancies that 
would have been encountered when switching between growth charts at age 24 months, 
which we recently described.20
Responders were defined by recovery from malnutrition and growth faltering resulting from 
untreated CF as indicated by catch-up weight gain to the level comparable to their birth 
weight z-score within 2 years of diagnosis.15 The rationale for this approach is based on 
findings that birth weights in infants with CF were similar21, 22 or only slightly lower22, 23 
than those of healthy infants, but a large percentage of CF children fall below the 5th 
percentile by the time of diagnosis.21, 22, 24 In addition, physical growth of infants and 
young children varies greatly due to intrauterine, genetic and nutritional influences. 
Therefore, recovery of weight to a level comparable to one’s birth weight z-score represents 
a more individualized indicator of treatment responsiveness than using a common reference 
level (such as weight > 5th or 10th percentile) for all children with CF.
Classification of growth patterns during 2–6 and 6–12 years of age
Growth pattern during age 2–6 years was evaluated using HTz and BMIz.8 WTz was not 
used to define growth pattern because WTz is influenced by both age and height. For 
example, a child may have a low WTz because he or she is short for age and not because of 
a low weight for height. On the other hand, BMIz is an independent indicator of weight for 
height proportion, thus provides a complimentary measure to HTz.
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The cumulative changes in HTz and BMIz during age 2–6 years (i.e., ΔHTz and ΔBMIz) 
were estimated using linear regression for each subject (i.e., slope multiplied by the 4-year 
interval). Thereafter, ΔHTz and ΔBMIz were evaluated relative to a one-channel difference 
(equivalent to approximately 0.67 Z-score) on the respective CDC growth charts.8 As 
illustrated in Figure 1, Responders whose ΔHTz and/or ΔBMIz increased or remained stable 
during ages 2–6 years were classified as “maintained” while Responders whose ΔHTz 
and/or ΔBMIz declined were classified as “not maintained”. On the other hand, Non-
responders whose ΔHTz and/or ΔBMIz increased during ages 2–6 years were classified as 
“improved”, while Non-responders whose ΔHTz and ΔBMIz remained stable or declined 
during age 2–6 years were classified as “not improved.”
The above process was repeated for ages 6–12 years, resulting in 8 possible subgroups 
(Figure 1). However, 3 subgroups had fewer than 5 patients. Therefore, we categorized 
growth patterns through age 12 years into 5 groups: 3 Responder groups (R12, R6, and R2, 
representing Responders who maintained growth improvement to age 12, 6, and 2 years, 
respectively) and 2 Non-responder groups (I6: Non-responders whose growth improved 
during 2–6 years of age and N6: Non-responders whose growth did not improve during 2–6 
years of age).
Pulmonary outcome measures at ages 6–12 years
Pulmonary function tests (PFT) were performed every 6 months beginning at age 4 years for 
the purpose of familiarizing and training young children with CF on this test, as described in 
detail previously.25 Only data validated with the Pediatric Alternate Spirometry System 
and/or ATS criteria were included,25 and the percentage of PFT measurements in children 
younger than 5.5 years did not differ significantly between Responders (6.2%) and Non-
Responders (7.0%). Percent predicted forced expiratory volume in one second (FEV1) were 
calculated using equations from Wang et al.26 Chest radiographs obtained at diagnosis, 2 and 
4 years of age, and annually thereafter were scored using the Brasfield system24 and the 
Wisconsin system25, 28, 29 by two raters (a pediatric pulmonologist and a thoracic 
radiologist). A total of 580 FEV1 measurements (7.6 ± 3.3 per patient) and 521 chest 
radiographs (6.9 ± 1.4 per patient) were analyzed.
Statistical Analysis
Analysis of variance was used to compare means when the data were normally distributed, 
and nonparametric analysis of variance was used when the data were skewed. Chi-square 
and Fisher’s exact test were used to compare categorical variables as appropriate. For 
longitudinal analyses, mixed effects models were used to evaluate the associations between 
growth and pulmonary outcomes with Responder status while adjusting for sex, diagnosis by 
NBS and birth weight z-scores. SAS 9.4 (SAS Institute, Inc, Cary, NC) and R 
(www.rproject.org) were used for data processing and statistical analyses. P-values < 0.05 
were considered statistically significant.
In consistent with Responder I and II studies,8,15 all analyses that compared growth and 
pulmonary outcomes were stratified or conducted separately by gastrointestinal phenotype, 
on the basis of the following rationale: 1) PS patients are at lower risk of malnutrition and 
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are able to achieve normal growth (i.e., mean weight- and length-for-age at approximately 
the 50th percentile) with energy intake at 99% of their recommended requirement,12 and 2) 
MI patients have been shown to experience poorer growth despite a higher energy intake 
than patients without MI with a similar age at diagnosis and treatment protocol.30
RESULTS
Characteristics of the study population
Table 1 compares the characteristics of the study populations across the three Responder 
studies. The 76 children with CF included in Responder III is a subset of children who 
completed follow-up to 12 years of age and had valid PFT measurements. Consistent with 
the Responder I and Responder II studies,8,15 Responders had significantly lower birth 
weights but higher height z-scores and BMI z-scores at 2 years of age compared to Non-
responders. None of the characteristics shown in Table 1 differ significantly across the 3 
Responder studies.
Growth patterns during 6–12 years of age in relation to prior growth and Responder status
Figure 1 shows that 62% (47 out of 76 CF children) were Responders. About three-quarters 
of the Responders (35 out of 47) followed their growth trajectories and maintained their 
growth improvement during 2–6 years; about two-thirds of the latter (22 out of 35) sustained 
the improvement to 12 years of age (R12), while the other one-third (13 out of 35) only 
maintained growth improvement to 6 years of age (R6). About a quarter of Responders (12 
out of 47) did not maintain their growth improvement beyond 2 years of age (R2). Among 
Non-responders, about three-quarters (22 out of 29) followed their growth trajectories and 
did not improve during 2–6 years (N6); moreover, 90% of N6 (20 out of 22) had no further 
improvement during 6–12 years. Only a quarter of Non-responders (7 out of 29) had 
improved growth during 2–6 years (I6), and none of them maintained the improvement 
through 12 years of age. These data demonstrate that growth patterns established early in life 
tend to persist and determine subsequent growth trajectories. Overall, of the 76 children with 
CF included in this study, 29% were R12, 17% R6, 16% R2, 9% I6 and 29% N6.
Growth and pulmonary status during 6–12 years of age by gastrointestinal phenotype
As shown in Figure 2, the MI subgroup had significantly lower height z-scores than the PI 
(p=0.014) and PS (p=0.005) groups, and significantly lower BMI scores than the PS group 
(p=0.003). Compared to the PS group, the PI group did not differ significantly in height z-
scores (p=0.13), but their BMI z-scores were lower (p=0.028).
Differences in height and BMI were also reflected in different Responder rates across the 
three phenotypes. The percentage of R12 was lowest in MI (12%), followed by PI (32%) and 
highest in PS (50%), while the percentage of N6 was higher in MI (47%) compared to PI 
(23%) and PS (33%). However, these differences did not reach statistical significance, most 
likely due to the small sample size of the PS group (n=6).
Regarding pulmonary outcomes, Figure 3 shows that FEV1 was significantly lower and 
declined at a faster rate during age 6–12 years in MI compared to PI (p=0.008) and PS 
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(p=0.024). Wisconsin CXR scores were also worst in MI, but the differences were only 
significant compared with PI.
These results provide evidence to support our previous approach in Responder I and II 
studies8,15 that delineating growth-pulmonary relationships in CF is best conducted by 
separate analysis for each phenotype, because differences in growth and pulmonary 
outcomes are not uniform across phenotypes, making it difficult to satisfactorily adjust the 
confounding by phenotype. Due to small sample sizes for the MI and PS groups and to 
provide comparison with Responder I and II studies,8,15 we conducted the remaining 
analyses below within the PI group only.
Growth and pulmonary status during 6–12 years of age in the PI group
Figure 4 shows that the three Responder groups (R12, R6 and R2) had significantly higher 
height z-scores than the two Non-responder groups (N6 and I6), p < 0.01 for all pairwise 
comparisons. Smaller differences in BMI z-scores were observed, but significant differences 
were observed in R12 and R6 compared to N6 and R2, p < 0.05 for all pairwise comparisons. 
The major difference between I6 and N6 is that the I6 group was very short (mean height z-
score <10th percentile) with normal BMI (~60th percentile), while the N6 group was taller 
(~20th percentile) but had lower BMI (~35th percentile). The I6 group is the shortest among 
the 5 groups, and their temporary improvement in growth during ages 2–6 years was due to 
increase in BMI and not in height status.
Figure 5 shows that all five groups had mean FEV1 >89%. R12 maintained the highest FEV1 
(97–99%) during ages 6–12 years that was consistently higher than N6 (89–93%), p=0.037. 
Both R6 and R2 had very good FEV1 at 6–8 years but their FEV1 declined around 10–12 
years of age. Wisconsin CXR scores revealed increasing severity of lung disease from 6 to 
12 years of age in all five groups (Figure 5). This finding supports our previous 
observation22 that the Wisconsin CXR score is more consistent and sensitive than FEV1 in 
detecting mild lung disease in young children with CF. R12 had the lowest (i.e., best) CXR 
scores throughout 6–12 years of age. The CXR scores for R12 were significantly better 
compared to N6 (p=0.016), I6 (p=0.034) and R6 (p=0.033).
Growth and pulmonary status at 12 years of age in the PI group
Figure 6 shows the associations between growth and pulmonary outcomes at age 12 years. 
FEV1 and Wisconsin CXR scores mirrored height z-scores, with the three Responder groups 
(R12, R6 and R2) better than the 2 Non-responder groups (N6 and I6). Overall, R12 had 
normal height and near normal BMI z-scores and the best FEV1 and Wisconsin CXR scores 
at age 12 years. This finding suggests that the longer adequate growth is maintained, the 
better the pulmonary outcomes at age 12 years.
DISCUSSION
Long-term outcome studies after NBS are rare but very much needed and valuable in the CF 
population. The present study examined growth and pulmonary outcomes more than a 
decade following diagnosis of CF through NBS in a prospectively followed cohort.12,13 
Results from the present study and our previous work8,15 advance our knowledge in 
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understanding growth patterns and their impact on lung disease progression in children with 
CF and PI from infancy through 12 years of age. Specifically, we demonstrated that growth 
patterns established early in life tend to persist and determine subsequent growth 
trajectories. That is, infants with CF and PI who recovered birth weight z-scores by 2 years 
of age (Responders) are more likely to maintain better height and BMI z-scores through 12 
years of age, while Non-responders are more likely to continue sub-optimal growth. Most 
noteworthy is that in our study cohort, none of the Non-responders achieved further catch-up 
growth consistently during 2–12 years. Temporary improvements in BMI were achieved for 
a minority of patients (n=7 during age 2–6 but not 6–12 years, and n=2 during age 6–12 but 
not 2–6 years), although height z-scores remained low. This illustrates how difficult it is to 
attain catch-up growth after the first 2 years of life, when growth rate is the highest during 
the life span. Our results are consistent with a recent report by Heltshe et al who showed that 
weight for age as early as 4 months of life appears to predict growth at 2 years of age.14
The most important clinical implication resulting from our findings is that, in children with 
CF and PI, early response (recovery of birth weight z-scores within 2 years of diagnosis) is 
not only essential in setting the foundation for future growth trajectory but also critical in 
increasing the likelihood of achieving better structural and functional lung disease at age 6 
years.8 However, in the present Responder III study, we found that the pulmonary benefit 
experienced by Responders at age 6 years were lessened at 12 years of age. That is, 
achieving Responder status at age 2 years alone is not sufficient to sustain normal lung 
function through 12 years of age: maintaining growth improvement through age 12 years is 
also needed. For example, our data in Figures 5 and 6 showed that both R2 and R6 had good 
FEV1 and CXR scores at 6 years, yet only R12 sustained normal measurements of FEV1 
(and had the smallest worsening in CXR scores) from 6 to 12 years. Temporary growth 
improvement in BMI but not height status, as was observed in the I6 group, was 
accompanied by transient increases in FEV1 that were not sustained at age 12 years and 
worsening CXR scores during 6–12 years of age.
An unanswered question is whether one can predict which infants would be Non-Responders 
(approximately one out of three infants) and which Non-Responders would continue growth 
faltering through 6 years of age (approximately three out of four Non-Responders), as well 
as which Responders will not maintain growth improvement beyond 2 years of age 
(approximately one out of four Responders), in order to intervene early with more 
aggressive nutrition therapy. Definitive answers to this question would be extremely difficult 
to obtain, as randomized clinical trials with multiple arms to test each potential determinant 
over 12 years are not feasible. In our Responder I study,15 early diagnosis through NBS with 
less severe malnutrition and pulmonary disease at the time of diagnosis, in conjunction with 
high dietary intakes of calories (at >120% of estimated requirement) and higher plasma 
levels of linoleic acid (the principle essential fatty acid) were found to increase the 
likelihood of being Responders. We concluded that frequent monitoring of plasma linoleic 
acid through assessment of plasma essential fatty acid profile is necessary and should be 
implemented in routine clinical care.15 However, current practice guidelines from the US 
Cystic Fibrosis Foundation10, 31, 32 still conclude that no sufficient evidence is present to 
recommend for or against essential fatty acid supplementation and that more research is 
needed. In our Responder II study,8 we found that Responders maintained adequate growth 
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through age 6 years despite lower caloric intake than Non-responders. This is likely due to 
the fact that poor growth in Non-responders prompted increase in caloric supplementation in 
order to promote catch-up growth, while Responders only needed to ingest sufficient 
calories to maintain current growth. Pseudomonas aeruginosa infection reduced the 
likelihood of being a Responder,15 but was not significantly associated with subsequent 
growth patterns during 2–6 years8 or 6–12 years of age (data not shown). By age 12 years, 
43 of 47 Non-Responders and 25 of 29 Responders had at least one recorded culture positive 
for Pseudomonas. We did not observe significant differences in Pseudomonas infections 
between Responders and Non-Responders. This may be due, at least partially, that very few 
subjects were never positive for Pseudomonas by 12 years of age.
Our study has two limitations. First, the sample size is relatively small, which limits our 
ability to perform subgroup comparisons or to adjust for potential confounders. Studies with 
large sample size are needed to validate our findings, especially for Non-responders with 
growth improvement at ages 2–6 years (the I6 group) and to investigate more in-depth in MI 
and PS patients. Second, our studies are observational, therefore, our findings on the impact 
of growth on pulmonary outcomes do not imply causality. Instead, it’s likely that 
associations are bidirectional, i.e., better growth leads to better pulmonary outcomes and 
vice versa.
CONCLUSIONS
Results from this long-term outcome study provide clear evidence that in infants with CF, 
early nutritional response (recovery of birth weight z-scores within 2 years of diagnosis) 
determines subsequent growth trajectories and increases the likelihood of achieving better 
growth, better lung function and less severe chest radiographic abnormalities through 12 
years of age. Further studies are needed to identify optimal CF interventions that can 
maximize the chance for achieving early growth recovery, as catch-up growth after infancy 
is difficult to attain.
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N6 Non-responders whose growth did not improve during 2–6 years of age
NBS Newborn screening
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R12 Responders who maintained their growth through 12 years of age
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Figure 1. 
Classification of growth patterns through 12 years of age. Responders recovered birth weight 
z-scores within 2 years of diagnosis while Non-responders did not. R12, R6, and R2 
maintained growth improvement to age 12, 6 and 2 years, respectively. I6 had growth 
improvement during age 2–6 years while N6 did not. (50)
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Figure 2. 
Comparison of growth during ages 6–12 years by gastrointestinal phenotype. MI: meconium 
ileus; PI: pancreatic insufficiency without MI; PS: pancreatic sufficiency. Differences among 
3 phenotypes were assessed by mixed effects models adjusting for sex, birth weight z-score 
and diagnosis by NBS; arrows with * indicate pairwise comparisons with p<0.05. (49)
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Figure 3. 
Comparison of pulmonary status during ages 6–12 years by gastrointestinal phenotype (see 
Figure 1 legend for abbreviations). Differences among 3 phenotypes were assessed by mixed 
effects models adjusting for sex, birth weight z-score and diagnosis by NBS; arrows with * 
indicate pairwise comparisons with p<0.05. (47)
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Figure 4. 
Comparison of growth during ages 6–12 years in PI patients among R12, R6, R2, N6 and I6 
(see Figure 1 legend for abbreviations). Differences were assessed by mixed effects models 
adjusting for sex, birth weight z-score and diagnosis by NBS; arrows with * indicate 
pairwise comparisons with p<0.05. (50)
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Figure 5. 
Comparison of pulmonary status during ages 6–12 years in PI patients among R12, R6, R2, 
N6 and I6 (see Figure 1 legend for abbreviations). Differences were assessed by mixed 
effects models adjusting for sex, birth weight z-score and diagnosis by NBS; arrows with * 
indicate pairwise comparisons with p<0.05. (51).
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Figure 6. 
Comparison of growth and pulmonary status at age 12 years in PI patients among R12, R6, 
R2, N6 and I6 (see Figure 1 legend for abbreviations). Differences were assessed by linear 
regression adjusting for sex, birth weight z-score and diagnosis by NBS. Pairwise 
comparisons of all 5 groups were performed, and bars with different alphabet letters are 
statistically different at p<0.05. (50)
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